184 reports of this reaction
2.5% of all PERPHENAZINE reports
#4 most reported adverse reaction
AKATHISIA is the #4 most commonly reported adverse reaction for PERPHENAZINE, manufactured by Actavis Pharma, Inc.. There are 184 FDA adverse event reports linking PERPHENAZINE to AKATHISIA. This represents approximately 2.5% of all 7,483 adverse event reports for this drug.
Patients taking PERPHENAZINE who experience akathisia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AKATHISIA is a less commonly reported adverse event for PERPHENAZINE, but still significant enough to appear in the safety profile.
In addition to akathisia, the following adverse reactions have been reported for PERPHENAZINE:
The following drugs have also been linked to akathisia in FDA adverse event reports:
AKATHISIA has been reported as an adverse event in 184 FDA reports for PERPHENAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
AKATHISIA accounts for approximately 2.5% of all adverse event reports for PERPHENAZINE, making it a notable side effect.
If you experience akathisia while taking PERPHENAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.